Your email has been successfully added to our mailing list.

×
0 -0.00330123796423659 -0.00436038514442914 -0.00962861072902342 -0.0110041265474553 0.00268225584594221 0.0110041265474553 0.0208528198074278
Stock impact report

Dicerna Pharmaceuticals: Buy The Dip [Seeking Alpha]

Dicerna Pharmaceuticals, Inc. (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com
Company Research Source: Seeking Alpha
Dicerna Pharmaceuticals: Buy The DipSummaryShares rose by as much as 225% in the past six months before the recent pullback.Pricing and participation in the secondary offering bodes well and I explain why.Their partnership with Boehringer Ingelheim adds credibility to the story.Lead GalXC clinical candidate DCR-PHXC has significant potential in treating PH and preclinical results were quite promising.They have additional irons in the fire, and although early-stage they could unlock value in 2018 as well. Show less Read more
Impact Snapshot
Event Time:
DRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for DRNA alerts
Opt-in for
DRNA alerts

from News Quantified
Opt-in for
DRNA alerts

from News Quantified